Key result
Elevated Lp(a) and OxPL-apoB linked to ~53% faster AS progression and increased major adverse events.
Why the study?
Elevated Lp(a) is associated with aortic stenosis, but the relationship of Lp(a) and oxidized phospholipids with AS progression and related events was unclear.
Observational (n=220)
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Elevated Lp(a) levels are associated with higher risk of most cardiovascular phenotypes, including myocardial infarction, stroke, peripheral arterial disease, calcific aortic valve disease, heart failure, cardiovascular and all-cause mortality, and possibly atrial fibrillation. Of these phenotypes, the strongest association is present with aortic stenosis.”
“Lp(a) is robustly associated with baseline and new-onset AVC but not with AVC progression, suggesting that Lp(a)-lowering interventions may be most effective in pre-calcific stages of aortic valve disease.”
“In the ASTRONOMER trial, a limited number of participants (n = 220) with mild-to-moderate AS (initial Vmax ≥ 2.5 m/s) who underwent repeated echocardiography exhibited faster Vmax progression with elevated Lp(a).”
Cohort study reveals faster aortic stenosis progression in patients with elevated lipoprotein(a) and oxidized phospholipids, suggesting a role for targeted lipid therapies.
BACKGROUND: Elevated lipoprotein(a) (Lp[a]) is associated with aortic stenosis (AS). Oxidized phospholipids (OxPL) are key mediators of calcification in valvular cells and are carried by Lp(a). OBJECTIVES: This study sought to determine whether Lp(a) and OxPL are associated with hemodynamic progression of AS and AS-related events. METHODS: OxPL on apolipoprotein B-100 (OxPL-apoB), which reflects the biological activity of Lp(a), and Lp(a) levels were measured in 220 patients with mild-to-moderate AS. The primary endpoint was the progression rate of AS, measured by the annualized increase in peak aortic jet velocity in m/s/year by Doppler echocardiography; the secondary endpoint was need for aortic valve replacement and cardiac death during 3.5 ± 1.2 years of follow-up. RESULTS: AS progression was faster in patients in the top tertiles of Lp(a) (peak aortic jet velocity: +0.26 ± 0.26 vs. +0.17 ± 0.21 m/s/year; p = 0.005) and OxPL-apoB (+0.26 ± 0.26 m/s/year vs. +0.17 ± 0.21 m/s/year; p = 0.01). After multivariable adjustment, elevated Lp(a) or OxPL-apoB levels remained independent predictors of faster AS progression. After adjustment for age, sex, and baseline AS severity, patients in the top tertile of Lp(a) or OxPL-apoB had increased risk of aortic valve replacement and cardiac death. CONCLUSIONS: Elevated Lp(a) and OxPL-apoB levels are associated with faster AS progression and need for aortic valve replacement. These findings support the hypothesis that Lp(a) mediates AS progression through its associated OxPL and provide a rationale for randomized trials of Lp(a)-lowering and OxPL-apoB-lowering therapies in AS. (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin [ASTRONOMER]; NCT00800800).
No takes yet. Share an insight, caveat, or question.
Capoulade et al. (2015) conducted an observational in mild-to-moderate aortic stenosis (n=220). Elevated lipoprotein(a) and OxPL-apoB (top tertiles) vs. Lower tertiles of lipoprotein(a) and OxPL-apoB was evaluated on Progression rate of aortic stenosis, measured by the annualized increase in peak aortic jet velocity in m/s/year (p=0.005). Patients in the top tertiles of Lp(a) and OxPL-apoB had faster aortic stenosis progression and an increased risk of aortic valve replacement and cardiac death.
Synapse has enriched 10 related papers. Consider them for comparative context: